Intellectual Property
(Non-confidential)

City of Hope
NATIONAL MEDICAL CENTER AND
BECKMAN RESEARCH INSTITUTE

Synthesis of Grossularines-1 and Analogs to Treat Cancer



DESCRIPTION

Grossularine-1 is a metabolite isolated from the ocean-dwelling tunicate, *Dendrodoa grossularia* that has been shown to exhibit potent anti-cancer effects. However, despite the promising biological activity of grossularine-1, the limited amounts that can be isolated from natural sources or available synthesis pathways have slowed investigation of these compounds as therapeutics.

This technology describes a novel and highly improved synthesis platform for grossularine-1 yielding significantly larger amounts of compound and covers and the use of grossularines-1 and related analogs for the treatment of cancer. Grossularine-1 analogs that have been developed using our novel synthesis platform show profound activity against a variety of human cancer cell lines and exhibit minimal toxicity. City of Hope investigators are currently pursuing structure/activity studies to optimize several candidate grossularine-1 analogs for their therapeutic potential.

KEY ASPECTS

- Grossularine-1 potently inhibits human cancer cell growth
- Novel synthesis platform has created grossularine-1 analogs with profound anti-cancer activity and minimal toxicity
- Novel synthesis platform yields considerably greater amounts of biologically active grossularine-1

INTELLECTUAL PROPERTY

Title	US Patent Number	Issued
Synthesis of Grossularines-1 and Analogs Thereof and Methods of Use	7,615,638	11/10/2009

CONTACT

Ryan Kelly, Ph.D.
Manager, Office of Technology Licensing
Telephone: (626) 471-9359 | Email: rykelly@coh.org